Eruption of bullae within psoriatic plaques: A rare adverse effect of narrow-band ultraviolet B (NB-UVB) phototherapy

Background: Since the best clinical response to dupilumab is achieved after 12–16 weeks, a combination therapy at the beginning of the treatment could be a helpful strategy to reach a faster response in patients with severe atopic dermatitis (AD). Objectives: To quantify the benefit of a combination of dupilumab treatment with a short course of narrow-band ultraviolet B (NB-UVB) phototherapy. Methods: In the present pilot study adult patients suffering from severe AD were enrolled with a 2:1 ratio to receive treatment with dupilumab alone or dupilumab plus NB-UVB phototherapy, for 12 weeks. After the twelfth week, all patients received dupilumab only. A follow-up visit took place after 16 weeks. Both clinician-oriented and patient-oriented scores were assessed at baseline (T0) and after 4 (T1), 12 (T2) and 16 (T3) weeks. Results: Forty-five adult patients were enrolled in the study. Both treatment regimens were well tolerated and very effective on all measured scores (EASI, SCORAD, BSA, NRS of itching, NRS of sleep loss, DLQI, POEM and HADS), but the combined regimen led to a more robust clinical improvement of lesions and relief of symptoms after 4 weeks. However, after 12 and 16 weeks, the additional therapeutic effect of phototherapy weakened. Conclusion: NB-UVB phototherapy can provide a faster remission of severe AD in the first few weeks of dupilumab therapy.

Download Full-text

Sitagliptin and Narrow-Band Ultraviolet-B for Moderate Psoriasis (DINUP): A Randomised Controlled Clinical Trial

Dermatology ◽

10.1159/000514494 ◽

2021 ◽

pp. 1-8

Author(s):

Maeve Lynch ◽

Anna Malara ◽

Irene Timoney ◽

Sebastian Vencken ◽

Tomas Ahern ◽

...

Keyword(s):

Narrow Band ◽

Disease Risk ◽

Cardiovascular Disease Risk ◽

Depression Scale ◽

Ultraviolet B ◽

Controlled Clinical Trial ◽

Significant Difference ◽

Randomised Controlled ◽

Uvb Phototherapy ◽

Psoriasis Severity

Background: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor licensed for the treatment of type 2 diabetes mellitus (T2DM), has been reported to improve psoriasis. Objective: We compared the effects of sitagliptin treatment, a DPP-4 inhibitor, in combination with narrow-band ultraviolet-B (NB-UVB) phototherapy compared to NB-UVB alone on psoriasis severity, quality of life, cardiovascular disease risk factors and immune parameters in people with moderate psoriasis without T2DM. Methods: In this 39-week, single-centre, randomised controlled trial, people were allocated randomly to receive sitagliptin for 24 weeks with NB-UVB or NB-UVB alone. The primary endpoint was the change in Psoriasis Area and Severity Index (PASI) from baseline to 24 weeks. We estimated that 120 participants would be needed to have 80% power to find a significant difference between the groups. Results: A total of 118 patients were randomised. The median (IQR) baseline PASI was 8.8 (7.5–11.6). At 24 weeks, the mean difference from baseline in PASI (–1.0 [95% CI –2.0 to 0.0]) was significantly larger in the sitagliptin/NB-UVB arm than in the NB-UVB-alone arm (p = 0.044). There were significant differences in the change in Hospital Anxiety and Depression Scale (–2.5 [95% CI –4.0 to –1.0]; p = 0.002) and EuroQol 5-item questionnaire (0.1 [95% CI 0.0–0.1]; p = 0.036) values from baseline to 24 weeks between the sitagliptin/NB-UVB and the NB-UVB-alone arm. There were no treatment-related serious adverse events. Conclusion: Sitagliptin therapy combined with NB-UVB phototherapy significantly improved psoriasis severity, albeit modestly, compared to NB-UVB phototherapy alone in patients with moderate psoriasis without T2DM.

Download Full-text

Narrow-band ultraviolet B and Conventional UVB phototherapy in Psoriasis: a Randomised Controlled Trial

American Journal of Applied Sciences ◽

10.3844/ajassp.2008.905.908 ◽

2008 ◽

Vol 5 (8) ◽

pp. 905-908 ◽

Cited By ~ 6

Author(s):

Yan Yuehua ◽

Ahmad T. Khalaf ◽

Zhai Xiaoxiang ◽

Wang Xinggang

Keyword(s):

Randomised Controlled Trial ◽

Narrow Band ◽

Controlled Trial ◽

Ultraviolet B ◽

Randomised Controlled ◽

Uvb Phototherapy

Download Full-text

Effect of Narrowband-UVB Phototherapy Treatment on Total Ferroxidase Activity and Ceruloplasmin Oxidase Activity in Sera of Iraqi Vitiligo Patients

Journal of Chemistry Education Research and Practice ◽

10.33140/jcerp.04.02.01 ◽

2020 ◽

Vol 4 (2) ◽

Keyword(s):

Oxidase Activity ◽

Narrow Band ◽

Specific Activity ◽

The Body ◽

Ultraviolet B ◽

Ion Concentration ◽

Narrowband Uvb ◽

Before And After ◽

Ferroxidase Activity ◽

Uvb Phototherapy

Vitiligo is an acquired pigmentary disorder in which white depigmented macules and patches of skin appear on different parts of the body, affecting all ages and both sexes equally. Focal, segmen-tal, generalized and universal are considered the most characteristic patterns of vitiligo. One of the most effective treatment of this disorder is using light therapy, and in particular ultraviolet (UV) light. Among them narrowband ultraviolet B phototherapy (NB-UVB) is the most widely used. Oxidative stress is considered to be one of the possible pathogenic events in melanocyte loss. Imbalance in the oxidant/antioxidant system have been demonstrated in blood of vitiligo patients. To demonstrate the safety of using NB-UVB phototherapy treatment in vitiligo Iraqi patients. Patients with vitiligo group were treated with NB-UVB regimen as three times weekly on non- consecutive days for a total of 20 sessions (about 2 months). Total ferroxidase (activity and specific activity), ceruloplasmin concentration, ceruloplasmin oxidase (activity and specific activity) and serum copper were determined in all participants before and after NBUVB phototherapy. The above biochemical parameters were measured in serum samples of 30 vitiligo patients before and after treatment with the narrow band UVB phototherapy. NB-UVB treatment was found to be associated with a significant reduction in copper ion concentration, but no significant differences in total ferroxidase (activity and specific activity), ceruloplasmin oxidase (activity and specific activity), and ceruloplasmin concentration. The present results provide evidence which support using narrow band UVB phototherapy as a safe method for vitiligo treatment.

Download Full-text

Clinical Efficiency of Narrow Band-Ultraviolet B Phototherapy and Methotrexate Therapy and their effects on Serum Tumor Necrosis Factor-Alpha in Patients with Cutaneous Lichen Planus.

10.22541/au.161556028.81077251/v1 ◽

2021 ◽

Author(s):

Mohammed Abu El-Hamd ◽

Hasan Mohamed Ibrahim ◽

Abdallah Elaiw Mohammed ◽

Eisa Mohammed

Keyword(s):

Narrow Band ◽

Ultraviolet B ◽

Necrosis Factor Alpha ◽

Treatment Groups ◽

Tnf Α ◽

Factor Alpha ◽

Α Level ◽

Uvb Phototherapy ◽

Necrosis Factor ◽

Serum Tumor Necrosis

Objective: This study aimed to assess the clinical efficiency of Narrow Band-Ultraviolet B (NB-UVB) phototherapy and methotrexate (MTX) therapy and their effects on serum tumor necrosis factor-alpha (TNF-α) in patients with cutaneous lichen planus (CLP). Methods: The present cohort study was carried out on 60 patients with CLP who attended the Out-patient Clinics of the Dermatology, Department, Faculty of Medicine, Faculty of Medicine, South Valley University between May 2018 and December 2019.The included patients were indiscriminately classified into two treatment groups; group A (30 patients), received NB-UVB phototherapy for three months and group B (30 patients), received MTX therapy for three months. All the patients were assessed clinically and TNF-α before and after treatments. Results: There were no statistically significant differences between the two groups of treatment regard clinical improvement after treatment (P=0.149). Regarding levels of TNF-α, there was a statistically significant difference between the two treatment groups after treatment (P=0.024). There was a statistically significant reduction in TNF-α level after treatment in the MTX group. Conclusion: This study concluded that NB-UVB phototherapy and MTX therapy were clinically effective in the treatment of patients with CLP. MTX therapy was more efficient in the reduction of TNF-α level than NB-UVB phototherapy in patients with CLP.

Download Full-text